• Home
  • About us
  • Work & Study
    • Visit us
    • PhD Pathways
  • Resources and Services
    • Guidelines
    • Clinical Trials
    • Resources for patients
    • Febrile Neutropenia
    • Sepsis Pathway
    • Antibiotic Allergy De- Labelling
    • Antimicrobial Stewardship
  • Research
    • Current projects
    • Recent Publications
  • Seminars
    • PMCC ID Unit Meeting
    • ACSIII Educational Day
    • NCIC Showcase 2025
  • Newsletter
  • Contact Us
  • Menu

National Centre for Infections in Cancer

  • Home
  • About us
  • Work & Study
    • Visit us
    • PhD Pathways
  • Resources and Services
    • Guidelines
    • Clinical Trials
    • Resources for patients
    • Febrile Neutropenia
    • Sepsis Pathway
    • Antibiotic Allergy De- Labelling
    • Antimicrobial Stewardship
  • Research
    • Current projects
    • Recent Publications
  • Seminars
    • PMCC ID Unit Meeting
    • ACSIII Educational Day
    • NCIC Showcase 2025
  • Newsletter
  • Contact Us
ibrutinib IFI.png

IFIs and Ibrutinib

October 05, 2017

While novel immunotherapies such as Immune checkpoint inhibitors and tyrosine kinase inhibitors have revolutionised cancer therapy the effect on the immunocompromised host is unclear. This recent review investigates the link between invasive fungal infection risk and new and emerging immunotherapies.

Prev / Next

Search news